Retatrutide is not yet an approved pharmaceutical product. All dosing data currently comes from clinical trial settings — Phase 1 and Phase 2 trials — which provides a research-derived reference framework for understanding how the compound has been studied. This article reviews that framework.
Phase 1 and Phase 2 Dosing Overview
The Phase 2 clinical trial for retatrutide, published in 2023, examined multiple dose levels in a randomised controlled setting. The trial used a structured dose escalation approach similar to the semaglutide STEP programme — starting at low doses and escalating over several months to reach various target maintenance doses.
The dose levels examined in Phase 2 included maintenance doses of 1 mg, 4 mg, 8 mg, and 12 mg per week. These doses are not directly comparable to semaglutide doses on a mg-for-mg basis, as the two compounds have different molecular weights, receptor affinity profiles, and potency characteristics.
Dose Escalation Protocol Used in Phase 2
| Parameter | Detail |
| Phase 2 target: 1 mg maintenance | Lower dose arm; used to establish minimum effective dose parameters |
| Phase 2 target: 4 mg maintenance | Mid-range dose; significant weight loss observed in published data |
| Phase 2 target: 8 mg maintenance | Higher dose arm; substantial weight loss with increased side effect frequency |
| Phase 2 target: 12 mg maintenance | Maximum dose studied; greatest weight loss observed; highest side effect burden |
| Escalation intervals | Dose increases at 4-week intervals to allow steady-state and tolerance adaptation |
| Duration | 48 weeks total treatment period in Phase 2 |
Published Efficacy Data from Phase 2
The Phase 2 results published in the New England Journal of Medicine in 2023 reported mean weight reductions from baseline at 48 weeks as follows (approximate values from published data):
At 1 mg: approximately 8.7% mean body weight reduction. At 4 mg: approximately 17.3%. At 8 mg: approximately 22.8%. At 12 mg: approximately 24.2%. The dose-response relationship was clear, with each higher dose producing greater weight reduction, though the marginal gain between 8 mg and 12 mg was smaller than between lower doses — a pattern consistent with approaching a pharmacological ceiling.
These results substantially exceeded what had been observed in comparable Phase 2 timeframes for semaglutide, though cross-trial comparisons must be made cautiously given differences in study populations, design, and measurement methods.
Tolerability Profile by Dose Level
Gastrointestinal side effects were the primary tolerability concern, consistent with the GLP-1R component. The incidence of nausea, vomiting, and diarrhoea increased with dose level. At 12 mg, the incidence of nausea was higher than typically reported for semaglutide at 2.4 mg, which is relevant to dose selection in research protocols — the highest dose may not always be the most practical.
An additional side effect signal in retatrutide data was increased heart rate, which is consistent with glucagon receptor activation (glucagon has known chronotropic effects). The heart rate increase was generally modest (approximately 4–8 bpm above baseline) but represents a distinguishing feature from semaglutide, where heart rate increases are smaller.
Implications for Research Protocols
For researchers using retatrutide as a research tool, the Phase 2 data provides practical guidance on dose selection and escalation. Key considerations:
Dose selection should be driven by the research question. If investigating the glucagon receptor contribution specifically, comparisons between lower doses (where GCGR contribution is proportionally smaller) and higher doses may be informative. If investigating body weight effects, the 4–8 mg range appears to offer a meaningful efficacy-tolerability balance based on Phase 2 data.
The longer washout period required after high-dose retatrutide (due to its ~7-day half-life) should be factored into crossover study designs — approximately 5 weeks minimum for full clearance.
Phase 3 trial results, when published, will provide substantially more data on dose-response relationships, tolerability, and long-term effects, and should be consulted when designing research protocols.
ℹ️ Retatrutide is not an approved drug. All information reflects clinical trial research data. This is educational context for researchers — not clinical or personal dosing guidance.